In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series C leads to $56mm for Achaogen

Executive Summary

Antibiotics developer Achaogen Inc. has raised $56mm in its Series C financing led by first-time backer Frazier Healthcare Ventures, which adds a board member and was joined by other new investor Alta Partners and returning shareholders 5AM Ventures, Arch Venture Partners, Domain Associates, Venrock Associates, Versant Ventures, and Wellcome Trust. The company will use some of the funds for a Phase II trial of its lead candidate ACHN490 for complicated urinary tract infections.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies